

**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claim 1 (original): A method of decreasing body weight in a patient, said method comprising administering a therapeutically effective amount of somatostatin or a somatostatin agonist to said patient.

Claim 2 (original): A method of claim 1, wherein said method comprises administering a therapeutically effective amount of a somatostatin agonist to said patient.

Claim 3 (original): A method of claim 2, wherein said somatostatin agonist is a somatostatin type-2 receptor agonist.

Claim 4 (original): A method of claim 2, wherein said somatostatin agonist is a somatostatin type-5 receptor agonist.

Claim 5 (original): A method of claim 3, wherein said somatostatin type-2 receptor agonist has a  $K_i$  of less than 2 nM for the somatostatin type-2 receptor.

Claim 6 (original): A method of claim 4, wherein said somatostatin type-5 receptor agonist has a  $K_i$  of less than 2 nM for the somatostatin type-5 receptor.

Claim 7 (original): A method of claim 2, wherein said somatostatin agonist is a somatostatin type-2 receptor selective agonist.

Claim 8 (original): A method of claim 2, wherein said somatostatin agonist is a somatostatin type-5 receptor selective agonist.

Claim 9 (original): A method of claim 7, wherein said somatostatin type-2 receptor selective agonist has a  $K_i$  for the somatostatin type-2 receptor that is at least 10 times less than the  $K_i$  for the somatostatin type-1, type-3, type-4, and type-5 receptors.

Claim 10 (original): A method of claim 8, wherein said somatostatin type-5 receptor selective agonist has a  $K_i$  for the somatostatin type-5 receptor that is at least 10 times less than the  $K_i$  for the somatostatin type-1, type-2, type-3, and type-4 receptors.

Claim 11 (original): A method of decreasing body weight in a patient, said method comprising administering a therapeutically effective amount of H-Cys-Phe-Phe-D-Trp-Lys-Thr-Phe-Cys-NH<sub>2</sub>, wherein a disulfide bond exists between the free thiols of two Cys residues.

Claim 12 (original): A method of claim 1, wherein said patient is an non-insulin-dependent diabetic human.

Claim 13 (original): A method of claim 2, wherein said patient is an non-insulin-dependent diabetic human.

Claim 14 (original): A method of claim 3, wherein said patient is an non-insulin-dependent diabetic human.

Claim 15 (original): A method of claim 4, wherein said patient is an non-insulin-dependent diabetic human.

App. No.: 09/423,684

Art Unit: 1653

Claim 16 (original): A method of claim 5, wherein said patient is an non-insulin-dependent diabetic human.

Claim 17 (original): A method of claim 6, wherein said patient is an non-insulin-dependent diabetic human.

Claim 18 (original): A method of claim 7, wherein said patient is an non-insulin-dependent diabetic human.

Claim 19 (original): A method of claim 8, wherein said patient is an non-insulin-dependent diabetic human.

Claim 20 (original): A method of claim 9, wherein said patient is an non-insulin-dependent diabetic human.

Claim 21 (original): A method of claim 10, wherein said patient is an non-insulin-dependent diabetic human.

Claim 22 (original): A method of claim 11, wherein said patient is an non-insulin-dependent diabetic human.

Claim 23 (original): A method according to claim 1 wherein the somatostatin agonist is

H-D- $\beta$ -Nal-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>,

H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys- $\beta$ -Nal-NH<sub>2</sub>,

H-D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Cys- $\beta$ -Nal-NH<sub>2</sub>,

H-D- $\beta$ -Nal-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>,

H-D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH<sub>2</sub>,

H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Pen-Thr-NH<sub>2</sub>,

H-D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-OH,

H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Pen-Thr-OH,

H-Gly-Pen-Phe-D-Trp-Lys-Thr-Cys-Thr-OH,

H-Phe-Pen-Tyr-D-Trp-Lys-Thr-Cys-Thr-OH,


H-Phe-Pen-Phe-D-Trp-Lys-Thr-Pen-Thr-OH,

H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-ol  
H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>,  
H-D-Trp-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH<sub>2</sub>,  
H-D-Trp-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>,  
H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH<sub>2</sub>,  
H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Trp-NH<sub>2</sub>,  
H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH<sub>2</sub>,  
Ac-D-Phe-Lys'-Tyr-D-Trp-Lys-Val-Asp-Thr-NH<sub>2</sub> (an amide bridge  
formed between Lys' and Asp),  
Ac-hArg(Et)<sub>2</sub>-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>,  
Ac-D-hArg(Et)<sub>2</sub>-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>,  
Ac-D-hArg(Bu)-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>,  
Ac-D-hArg(Et)<sub>2</sub>-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>,  
Ac-L-hArg(Et)<sub>2</sub>-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>,  
Ac-D-hArg(CH<sub>2</sub>CF<sub>3</sub>)<sub>2</sub>-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>,  
Ac-D-hArg(CH<sub>2</sub>CF<sub>3</sub>)<sub>2</sub>-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>,  
Ac-D-hArg(CH<sub>2</sub>CF<sub>3</sub>)<sub>2</sub>-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Phe-NH<sub>2</sub>,  
Ac-D-hArg(CH<sub>2</sub>CF<sub>3</sub>)<sub>2</sub>-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NHET,  
Ac-L-hArg(CH<sub>2</sub>-CF<sub>3</sub>)<sub>2</sub>-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>,  
Ac-D-hArg(CH<sub>2</sub>CF<sub>3</sub>)<sub>2</sub>-Gly-Cys-Phe-D-Trp-Lys(Me)-Thr-Cys-Thr-NH<sub>2</sub>,  
Ac-D-hArg(CH<sub>2</sub>CF<sub>3</sub>)<sub>2</sub>-Gly-Cys-Phe-D-Trp-Lys(Me)-Thr-Cys-Thr-NHET,  
Ac-hArg(CH<sub>3</sub>, hexyl)-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>,  
H-hArg(hexyl)<sub>2</sub>-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>,  
Ac-D-hArg(Et)<sub>2</sub>-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NHET,  
Ac-D-hArg(Et)<sub>2</sub>-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Phe-NH<sub>2</sub>,  
Propionyl-D-hArg(Et)<sub>2</sub>-Gly-Cys-Phe-D-Trp-Lys(iPr)-Thr-Cys-Thr-NH<sub>2</sub>,  
Ac-D-β-Nal-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Gly-hArg(Et)<sub>2</sub>-NH<sub>2</sub>,  
Ac-D-Lys(iPr)-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>,  
Ac-D-hArg(CH<sub>2</sub>CF<sub>3</sub>)<sub>2</sub>-D-hArg(CH<sub>2</sub>CF<sub>3</sub>)<sub>2</sub>-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-  
Thr-NH<sub>2</sub>,  
Ac-D-hArg(CH<sub>2</sub>CF<sub>3</sub>)<sub>2</sub>-D-hArg(CH<sub>2</sub>CF<sub>3</sub>)<sub>2</sub>-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-  
Phe-NH<sub>2</sub>,  
Ac-D-hArg(Et)<sub>2</sub>-D-hArg(Et)<sub>2</sub>-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>,  
Ac-Cys-Lys-Asn-4-Cl-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-Ser-D-Cys-NH<sub>2</sub>,  
H-Bmp-Tyr-D-Trp-Lys-Val-Cys-Thr-NH<sub>2</sub>,

H-Bmp-Tyr-D-Trp-Lys-Val-Cys-Phe-NH<sub>2</sub>,  
H-Bmp-Tyr-D-Trp-Lys-Val-Cys-p-Cl-Phe-NH<sub>2</sub>,  
H-Bmp-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH<sub>2</sub>,  
H-D-β-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH<sub>2</sub>,  
H-D-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH<sub>2</sub>,  
H-D-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-β-Nal-NH<sub>2</sub>,  
H-pentafluoro-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH<sub>2</sub>,  
Ac-D-β-Nal-Cys-pentafluoro-Phe-D-Trp-Lys-Val-Cys-Thr-NH<sub>2</sub>,  
H-D-β-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH<sub>2</sub>,  
H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH<sub>2</sub>,  
H-D-β-Nal-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH<sub>2</sub>,  
H-D-p-Cl-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH<sub>2</sub>,  
Ac-D-p-Cl-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH<sub>2</sub>,  
H-D-Phe-Cys-β-Nal-D-Trp-Lys-Val-Cys-Thr-NH<sub>2</sub>,  
H-D-Phe-Cys-Tyr-D-Trp-Lys-Cys-Thr-NH<sub>2</sub>,  
cyclo(Pro-Phe-D-Trp-N-Me-Lys-Thr-Phe),  
cyclo(Pro-Phe-D-Trp-N-Me-Lys-Thr-Phe),  
cyclo(Pro-Phe-D-Trp-Lys-Thr-N-Me-Phe),  
cyclo(N-Me-Ala-Tyr-D-Trp-Lys-Thr-Phe),  
cyclo(Pro-Tyr-D-Trp-Lys-Thr-Phe),  
cyclo(Pro-Phe-D-Trp-Lys-Thr-Phe),  
cyclo(Pro-Phe-L-Trp-Lys-Thr-Phe),  
cyclo(Pro-Phe-D-Trp(F)-Lys-Thr-Phe),  
cyclo(Pro-Phe-Trp(F)-Lys-Thr-Phe),  
cyclo(Pro-Phe-D-Trp-Lys-Ser-Phe),  
cyclo(Pro-Phe-D-Trp-Lys-Thr-p-Cl-Phe),  
cyclo(D-Ala-N-Me-D-Phe-D-Thr-D-Lys-Trp-D-Phe),  
cyclo(D-Ala-N-Me-D-Phe-D-Val-Lys-D-Trp-D-Phe),  
cyclo(D-Ala-N-Me-D-Phe-D-Thr-Lys-D-Trp-D-Phe),  
cyclo(D-Abu-N-Me-D-Phe-D-Val-Lys-D-Trp-D-Tyr),  
cyclo(Pro-Tyr-D-Trp-t-4-AchxAla-Thr-Phe),  
cyclo(Pro-Phe-D-Trp-t-4-AchxAla-Thr-Phe),  
cyclo(N-Me-Ala-Tyr-D-Trp-Lys-Val-Phe),  
cyclo(N-Me-Ala-Tyr-D-Trp-t-4-AchxAla-Thr-Phe),  
cyclo(Pro-Tyr-D-Trp-4-Amphe-Thr-Phe),

cyclo(Pro-Phe-D-Trp-4-Amphe-Thr-Phe) ,  
 cyclo(N-Me-Ala-Tyr-D-Trp-4-Amphe-Thr-Phe) ,  
 cyclo(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba) ,  
 cyclo(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba-Gaba) ,  
 cyclo(Asn-Phe-D-Trp-Lys-Thr-Phe) ,  
 cyclo(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-NH(CH<sub>2</sub>)<sub>4</sub>CO) ,  
 cyclo(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-β-Ala) ,  
 cyclo(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-D-Glu)-OH ,  
 cyclo(Phe-Phe-D-Trp-Lys-Thr-Phe) ,  
 cyclo(Phe-Phe-D-Trp-Lys-Thr-Phe-Gly) ,  
 cyclo(Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba) ,  
 cyclo(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Gly) ,  
 cyclo(Asn-Phe-Phe-D-Trp(F)-Lys-Thr-Phe-Gaba) ,  
 cyclo(Asn-Phe-Phe-D-Trp(NO<sub>2</sub>)-Lys-Thr-Phe-Gaba) ,  
 cyclo(Asn-Phe-Phe-Trp(Br)-Lys-Thr-Phe-Gaba) ,  
 cyclo(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe(I)-Gaba) ,  
 cyclo(Asn-Phe-Phe-D-Trp-Lys-Thr-Tyr(But)-Gaba) ,  
 cyclo(Bmp-Lys-Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-Pro-Cys)-OH ,  
 cyclo(Bmp-Lys-Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-Pro-Cys)-OH ,  
 cyclo(Bmp-Lys-Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-Tpo-Cys)-OH ,  
 cyclo(Bmp-Lys-Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-MeLeu-Cys)-OH ,  
 cyclo(Phe-Phe-D-Trp-Lys-Thr-Phe-Phe-Gaba) ,  
 cyclo(Phe-Phe-D-Trp-Lys-Thr-Phe-D-Phe-Gaba) ,  
 cyclo(Phe-Phe-D-Trp(5F)-Lys-Thr-Phe-Phe-Gaba) ,  
 cyclo(Asn-Phe-Phe-D-Trp-Lys(Ac)-Thr-Phe-NH-(CH<sub>2</sub>)<sub>3</sub>-CO) ,  
 cyclo(Lys-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba) ,  
 cyclo(Lys-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba) ,  
 cyclo(Orn-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba) ,  
 H-Cys-Phe-Phe-D-Trp-Lys-Thr-Phe-Cys-NH<sub>2</sub> ,  
 H-Cys-Phe-Phe-D-Trp-Lys-Ser-Phe-Cys-NH<sub>2</sub> ,  
 H-Cys-Phe-Tyr-D-Trp-Lys-Thr-Phe-Cys-NH<sub>2</sub> or  
 H-Cys-Phe-Tyr(I)-D-Trp-Lys-Thr-Phe-Cys-NH<sub>2</sub> .

Claim 24 (original): A method according to claim 1 wherein the somatostatin agonist is



$A^1$  is a D- or L- isomer of Ala, Leu, Ile, Val, Nle, Thr, Ser,  $\beta$ -Nal,  $\beta$ -Pal, Trp, Phe, 2,4-dichloro-Phe, pentafluoro-Phe, p-X-Phe, or o-X-Phe, wherein X is  $CH_3$ , Cl, Br, F, OH,  $OCH_3$  or  $NO_2$ ;

$A^2$  is Ala, Leu, Ile, Val, Nle, Phe,  $\beta$ -Nal, pyridyl-Ala, Trp, 2,4-dichloro-Phe, pentafluoro-Phe, o-X-Phe, or p-X-Phe, wherein X is  $CH_3$ , Cl, Br, F, OH,  $OCH_3$  or  $NO_2$ ;

$A^3$  is pyridyl-Ala, Trp, Phe,  $\beta$ -Nal, 2,4-dichloro-Phe, pentafluoro-Phe, o-X-Phe, or p-X-Phe, wherein X is  $CH_3$ , Cl, Br, F, OH,  $OCH_3$  or  $NO_2$ ;

$A^6$  is Val, Ala, Leu, Ile, Nle, Thr, Abu, or Ser;

$A^7$  is Ala, Leu, Ile, Val, Nle, Phe,  $\beta$ -Nal, pyridyl-Ala, Trp, 2,4-dichloro-Phe, pentafluoro-Phe, o-X-Phe, or p-X-Phe, wherein X is  $CH_3$ , Cl, Br, F, OH,  $OCH_3$  or  $NO_2$ ;

$A^8$  is a D- or L-isomer of Ala, Leu, Ile, Val, Nle, Thr, Ser, Phe,  $\beta$ -Nal, pyridyl-Ala, Trp, 2,4-dichloro-Phe, pentafluoro-Phe, p-X-Phe, or o-X-Phe, wherein X is  $CH_3$ , Cl, Br, F, OH,  $OCH_3$  or  $NO_2$ ;

each  $R_1$  and  $R_2$ , independently, is H, lower acyl or lower alkyl; and  $R_3$  is OH or  $NH_2$ ; provided that at least one of  $A^1$  and  $A^8$  and one of  $A^2$  and  $A^7$  must be an aromatic amino acid; and further provided that  $A^1$ ,  $A^2$ ,  $A^7$  and  $A^8$  cannot all be aromatic amino acids.

Claim 25 (original): A method according to claim 24 wherein the linear somatostatin agonist is

H-D-Phe-p-chloro-Phe-Tyr-D-Trp-Lys-Thr-Phe-Thr- $NH_2$ ,

H-D-Phe-p- $NO_2$ -Phe-Tyr-D-Trp-Lys-Val-Phe-Thr- $NH_2$ ,

H-D-Nal-p-chloro-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr- $NH_2$ ,

H-D-Phe-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr- $NH_2$ ,

H-D-Phe-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr- $NH_2$ ,




H-D-Phe-p-chloro-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr- $NH_2$  or

H-D-Phe-Ala-Tyr-D-Trp-Lys-Val-Ala- $\beta$ -D-Nal- $NH_2$ .


App. No.: 09/423,684

Art Unit: 1653

Claim 26 (original): A method according to claim 1 wherein the somatostatin agonist is



or



Claim 27 (original): A method according to claim 1 wherein said patient is obese.

Claim 28 (original): A method according to claim 3 wherein said patient is obese.

Claim 29 (original): A method according to claim 4 wherein said patient is obese.

Claim 30 (original): A method according to claim 7 wherein said patient is obese.

Claim 31 (original): A method according to claim 8 wherein said patient is obese.

Claim 32 (original): A method according to claim 11 wherein said patient is obese.

Claim 33 (canceled)

Claim 34 (canceled)

Claim 35 (canceled)

Claim 36 (canceled)

Claim 37 (canceled)